Patents Represented by Attorney, Agent or Law Firm Audrey F. Sher
  • Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
    Patent number: 6399773
    Abstract: The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH mediated diseases, such as transplant rejection and autoimmune diseases.
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: June 4, 2002
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Chunjian Liu, T. G. Murali Dhar, Henry H. Gu, Edwin J. Iwanowicz, Katerina Leftheris, William J. Pitts
  • Modified forms of Hepatitis C NS3 protease for facilitating inhibitor screening and structural studies of protease: inhibitor complexes
    Patent number: 6333186
    Abstract: The present invention relates to modified Hepatitis C NS3 proteases and modified Hepatitis C NS4a-NS3 fusion proteases. These proteins are highly soluble and are useful for NMR spectroscopy, X-ray crystallography, and inhibitor screening. DNA constructs are also provided.
    Type: Grant
    Filed: January 6, 2000
    Date of Patent: December 25, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael Wittekind, Steven Weinheimer, Yaqun Zhang, Valentina Goldfarb
  • Enzymatic oxidative deamination process
    Patent number: 6261810
    Abstract: The present invention concerns an enzymatic oxidative deamination process of a dipeptide monomer to prepare an intermediate useful to prepare compounds having endopeptidase and angiotensin converting enzyme inhibition activity.
    Type: Grant
    Filed: August 31, 1999
    Date of Patent: July 17, 2001
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ramesh N. Patel, Amit Banerjee, Venkata B. Nanduri, Laszlo J. Szarka, Shankar Swaminathan, John J. Venit, Jerome L. Moniot, David A. Lust, Sushil K. Srivastava
  • Imidazoquinoxaline protein tyrosine kinase inhibitors
    Patent number: 6235740
    Abstract: Novel imidazoquinoxalines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.
    Type: Grant
    Filed: June 15, 1998
    Date of Patent: May 22, 2001
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Joel C. Barrish, Ping Chen, Jagabandhu Das, Edwin J. Iwanowicz, Derek J. Norris, Ramesh Padmanabha, Jacques Y. Roberge, Gary L. Schieven
  • Lysosomal enzyme-cleavable antitumor drug conjugates
    Patent number: 6214345
    Abstract: The present invention relates to drug-ligand conjugates wherein the drug is linked to the ligand through a protein peptide linker and a connector, a process for the preparation of the conjugates, method of controlling the growth of undesirable cells, pharmaceutical compositions, and intermediates thereof.
    Type: Grant
    Filed: May 14, 1993
    Date of Patent: April 10, 2001
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Raymond Armand Firestone, Gene Michael Dubowchik
  • Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
    Patent number: 6132992
    Abstract: The present invention provides an expression vector encoding monospecific or bispecific fusion protein. In one embodiment the expression vector encodes a monospecific fusion protein, which vector comprises a recombinant monospecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen. In another embodiment the expression vector encodes a bispecific fusion protein, which vector comprises a recombinant bispecific single chain cassette comprising a DNA sequence encoding a first binding domain capable of binding a cell surface antigen and a DNA sequence encoding a second binding domain capable of binding a cell surface antigen, each domain capable of binding a different antigen. The present invention also provides a method for producing a biologically active monospecific or bispecific fusion protein in a mammalian cell.
    Type: Grant
    Filed: October 5, 1995
    Date of Patent: October 17, 2000
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Jeffrey A. Ledbetter, Lisa K. Gilliland, Martha S. Hayden, Peter S. Linsley, Jurgen Bajorath, H. Perry Fell
  • Antibodies against human CD40
    Patent number: 6051228
    Abstract: The Applicants have discovered a novel antibody, more specifically a chimerized anti-human CD40 monoclonal antibody, which blocks the interaction between gp39 and CD40. The anti-CD40 antibodies of the present invention are effective in modulating humoral immune responses against T cell-dependent antigens, collagen induced arthritis, and skin transplantation, and are also useful for their anti-inflammatory properties.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: April 18, 2000
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Alejandro A. Aruffo, Diane Hollenbaugh, Anthony W. Siadak, Karen K. Berry, Linda Harris, Barbara A. Thorne, Jurgen Bajorath
  • D-amino acid oxidase promoter from T. variabilis
    Patent number: 6025159
    Abstract: A D-amino acid oxidase promoter isolated from T. variabilis has been incorporated into S. cerevisiae expression vectors to increase the expression of heterologous genes. The heterologous promoter has been placed upstream of selective markers, auxotrophic nutritional and/or dominant selectable markers. Because the promoter is from another yeast specie, it is weakly recognized by and S. cerevisiae. To compensate for the weak transcripts of selectable marker genes transcribed from the weak heterologous promoter, the plasmid containing the gene of the interest is amplified leading to a higher expression of protein of interest.
    Type: Grant
    Filed: June 18, 1998
    Date of Patent: February 15, 2000
    Assignee: Bristol-Myers Squibb Company
    Inventors: Suo W. Liu, Thomas Franceschini
  • Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
    Patent number: 5990109
    Abstract: Novel heterocyclo-substituted imidazopyrazines and salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds in the treatment of protein tyrosine kinase-associated disorders such as immunologic disorders.
    Type: Grant
    Filed: March 4, 1999
    Date of Patent: November 23, 1999
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Ping Chen, Derek J. Norris, Joel C. Barrish, Edwin J. Iwanowicz
  • Promoter of the retinoic acid receptor gene for directing gene expression
    Patent number: 5922596
    Abstract: An isolated DNA sequence capable of directing gene expression comprising a hRAR-.alpha. promoter or a hRAR-.alpha. promoter element, expression vectors containing the DNA sequence and host cells containing the expression vectors.
    Type: Grant
    Filed: December 10, 1990
    Date of Patent: July 13, 1999
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Pierre Chambon, Nigel J. Brand, Martin Petkovich
  • Method for inactivation of protein function
    Patent number: 5919650
    Abstract: Method for inactivating the function produced by a protein using an intracellularly expressed antibody or fragment thereof.
    Type: Grant
    Filed: April 22, 1990
    Date of Patent: July 6, 1999
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Mariano Barbacid, Ximena Montano
  • Monoclonal antibodies which bind mevalonate kinase
    Patent number: 5898068
    Abstract: Monoclonal antibodies which bind mevalonate kinase, hybrid cell lines which produce these monoclonal antibodies, and immunoassay methods for detecting mevalonate kinase using these monoclonal antibodies.
    Type: Grant
    Filed: May 29, 1990
    Date of Patent: April 27, 1999
    Assignee: Bristol-Myers Squibb Company
    Inventor: Kendra B. Eager
  • Cephalosporin esterase gene from Rhodosporidium toruloides
    Patent number: 5869309
    Abstract: The instant invention provides nucleic acid molecules encoding cephalosporin esterase from Rhodosporidium toruloides. In addition, the invention provides isolated cephalosporin esterase, expression vectors, host cells, and methods of producing cephalosporin esterase.
    Type: Grant
    Filed: September 17, 1997
    Date of Patent: February 9, 1999
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Michael Politino, Sean M. Tonzi, John J. Usher, William V. Burnett, Guna Romancik